<DOC>
	<DOCNO>NCT00062309</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray source radiation kill tumor cell . It yet know radiation therapy regimen effective treat prostate cancer . PURPOSE : This randomized phase III trial compare two different regimen radiation therapy see well work treat patient stage II stage III prostate cancer .</brief_summary>
	<brief_title>Comparison Two Radiation Therapy Regimens Treating Patients With Stage II Stage III Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy conventional intensity-modulated radiotherapy ( IMRT ) v hypofractionated IMRT , term freedom biochemical failure men intermediate- high-risk prostate cancer . - Compare local control , freedom distant metastasis , overall survival patient treat regimen . - Determine local failure , use biopsy prostate , objective test ( prostate-specific antigen , ultrasound , digital rectal exam ) suggest relapse patient . - Compare extent disease eradication use biopsy prostate 2 year therapy patient . - Compare quality life patient treat regimen . - Determine impact regimens patient preference utility . OUTLINE : This randomize study . Patients stratify accord pretreatment prostate-specific antigen ( great 10 ng/mL v great 10 20 ng/mL v great 20 ng/mL ) , Gleason score ( 5-7 v 8-10 ) , risk status ( high risk v intermediate risk ) . Patients randomize 1 2 treatment arm . - Arm I : Patients undergo conventional intensity-modulated radiotherapy ( IMRT ) 5 day week 7.5 week absence disease progression unacceptable toxicity . - Arm II : Patients undergo hypofractionated IMRT 5 day week 5 week absence disease progression unacceptable toxicity . Patients high-risk disease also undergo androgen deprivation therapy 2 year . Quality life assess baseline , every 6 month 1 year , annually 4 year . Patients follow 3 month , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 300 patient ( 150 per treatment arm ) accrue study within 3 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Clinical stage T1bT3c disease No clinical radiographic evidence metastasis Prostatespecific antigen ( PSA ) less 80 ng/mL Gleason score least 5 One follow criterion must meet : PSA great 10 ng/mL Gleason score great 6 T2b great palpable disease Three biopsy core involve Gleason score least 5 PATIENT CHARACTERISTICS : Age Not specify Performance status Zubrod 01 Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Other No medical condition would preclude study participation No active malignancy within past 5 year except nonmetastatic skin cancer early stage chronic lymphocytic leukemia ( welldifferentiated small cell lymphocytic leukemia ) Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy No 4 month prior androgen deprivation therapy Neoadjuvant adjuvant androgen deprivation therapy allow highrisk disease Radiotherapy No prior pelvic radiotherapy Surgery No prior plan radical prostate surgery</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>stage II prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>adenocarcinoma prostate</keyword>
</DOC>